Darzalex 100mg-IND (Daratumumab Vials) 100mg/5ml

Darzalex 100mg-IND (daratumumab) is an injectable prescription medication used in certain cancer treatments. This 100mg/5ml vial form is stored between 2-8°C for stability. Daratumumab belongs to a class of drugs designed to target specific proteins in the body.

Strength

100mg/5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Janssen - Cilag AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Daratumumab is primarily used to treat multiple myeloma, a type of blood cancer. It may be prescribed for patients who have received prior treatments or as part of combination therapy. This medication works by helping the immune system recognize and attack cancer cells. Patients often inquire 'what is daratumumab used for' when discussing treatment options with healthcare providers.

Side Effects

Daratumumab may help slow the progression of disease in eligible patients. Common effects include infusion-related reactions during administration, such as chills or nausea. Some patients report fatigue or changes in blood cell counts while receiving treatment. These effects vary by individual and should be monitored by a healthcare professional.

Precautions & Warnings

This medication requires careful handling and should only be administered by trained medical staff. Patients must store vials at 2-8°C and protect them from light. Keep out of reach of children and pets. Always inform your healthcare provider about all medications and conditions before starting daratumumab.

Avoid Interactions

Daratumumab may interact with other drugs that affect the immune system, such as corticosteroids or immunosuppressants. Combining it with certain vaccines or live therapies could pose risks. Alcohol and over-the-counter supplements should be discussed with a doctor. Always review your full medication list with your healthcare team.

References

Frequently Asked Questions

Daratumumab is used to treat multiple myeloma, a cancer of plasma cells in the bone marrow.

It is given as an intravenous infusion by healthcare professionals in a clinical setting.

Infusion reactions like chills, nausea, or fatigue are commonly reported during treatment.

No, daratumumab vials must be stored between 2-8°C and protected from light.

Yes, it may interact with immunosuppressants, vaccines, or other cancer therapies; consult your doctor.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.